Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 24, 2026

SK pharmteco et Prozomix annoncent une collaboration stratégique visant à renforcer leurs capacités en matière de biocatalyse pour la fabrication de médicaments à l’échelle mondiale

View original at globenewswire.com
SK pharmteco et Prozomix annoncent une collaboration stratégique visant à renforcer leurs capacités en matière de biocatalyse pour la fabrication de médicaments à l’échelle mondiale RANCHO CORDOVA, Californie, 24 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco, une organisation mondiale de premier plan spécialisée dans le d…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As drug molecules become increasingly complex, the use of enzymes offers a greener, more selective, and more cost-effective alternative to traditional chemical synthesis

    60% confidence

  • Prozomix's ability to quickly deliver large quantities of optimized enzymes coupled with SK pharmteco's manufacturing excellence ensures clients can transition from discovery phase to commercial-scale production with unmatched speed and reliability

    60% confidence

  • SK pharmteco's mission is to forge strong relationships with industry leaders based on trust, quality, and a shared commitment to reliably deliver medicines meeting more demanding standards

    60% confidence

  • The partnership with SK pharmteco will fully exploit the potential of Prozomix's enzyme range in the most demanding pharmaceutical applications

    60% confidence

  • Prozomix has earned a global reputation for reducing risks associated with early bioprocess development through its highly diverse enzyme sets and rapid scale-up capabilities

    60% confidence

  • Integration of Prozomix's enzymatic diversity into SK pharmteco's global R&D and manufacturing process complements their current technology platforms and helps offer clients more innovative and sustainable solutions

    60% confidence

Cited in these Via News reports